Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedSep 01, 2026
DataAggregated Company Financials
Companies20
  • 7D-1.9%
  • 3M7.4%
  • 1Y-16.2%
  • YTD-9.6%

Over the last 7 days, the Healthcare industry has dropped 1.9%, driven by a pullback from Novo Nordisk of 2.3%. Overall the industry is down 16% in 12 months. Looking forward, earnings are forecast to grow by 4.4% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 02 Sep 2026DKK 1.8tDKK 468.2bDKK 137.3b23.3x12.8x3.8x
Fri, 31 Jul 2026DKK 1.9tDKK 469.1bDKK 147.1b20.6x13x4.1x
Sun, 28 Jun 2026DKK 1.8tDKK 469.3bDKK 147.1b19.7x12.4x3.9x
Tue, 26 May 2026DKK 1.7tDKK 468.7bDKK 147.0b20.4x11.6x3.6x
Thu, 23 Apr 2026DKK 1.5tDKK 447.3bDKK 129.9b19x11.7x3.4x
Sat, 21 Mar 2026DKK 1.5tDKK 447.7bDKK 130.0b16.2x11.2x3.2x
Mon, 16 Feb 2026DKK 1.8tDKK 448.0bDKK 134.8b15.7x13.5x4.1x
Wed, 14 Jan 2026DKK 2.2tDKK 454.0bDKK 137.0b18.6x16.2x4.9x
Fri, 12 Dec 2025DKK 1.9tDKK 453.7bDKK 136.9b17.4x14.1x4.2x
Sun, 09 Nov 2025DKK 1.8tDKK 453.0bDKK 135.7b17.6x13.1x3.9x
Tue, 07 Oct 2025DKK 2.2tDKK 447.4bDKK 141.7b18.4x15.8x5x
Thu, 04 Sep 2025DKK 2.1tDKK 447.5bDKK 141.8b24.2x14.9x4.7x
Sat, 02 Aug 2025DKK 1.8tDKK 423.5bDKK 124.6b29.3x14.6x4.3x
Mon, 30 Jun 2025DKK 2.4tDKK 423.1bDKK 124.5b30.5x19.2x5.7x
Wed, 28 May 2025DKK 2.5tDKK 423.9bDKK 124.7b25.8x20.3x6x
Fri, 25 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.9x18.8x5.6x
Sun, 23 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.7x23.4x6.9x
Tue, 18 Feb 2025DKK 3.1tDKK 409.9bDKK 121.5b26.7x25.3x7.5x
Thu, 16 Jan 2025DKK 3.2tDKK 387.5bDKK 111.3b28.8x29x8.3x
Sat, 14 Dec 2024DKK 3.9tDKK 387.4bDKK 111.3b30.5x34.9x10x
Mon, 11 Nov 2024DKK 3.9tDKK 386.3bDKK 110.7b32.7x35.1x10.1x
Wed, 09 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.4x38.4x11x
Fri, 06 Sep 2024DKK 4.5tDKK 371.9bDKK 107.2b35x42.3x12.2x
Sun, 04 Aug 2024DKK 4.5tDKK 355.3bDKK 106.3b36.6x42x12.6x
Tue, 02 Jul 2024DKK 5.0tDKK 355.3bDKK 106.2b34.2x47.4x14.2x
Thu, 30 May 2024DKK 4.6tDKK 355.3bDKK 106.2b36.5x43.3x13x
Sat, 27 Apr 2024DKK 4.5tDKK 341.4bDKK 99.6b33.1x45.3x13.2x
Mon, 25 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.7x45.7x13.4x
Wed, 21 Feb 2024DKK 4.3tDKK 340.1bDKK 98.9b38x43.9x12.8x
Fri, 19 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.8x42.1x11.8x
Sun, 17 Dec 2023DKK 3.5tDKK 320.5bDKK 90.0b32.9x38.7x10.9x
Tue, 14 Nov 2023DKK 3.6tDKK 320.0bDKK 90.1b31.5x39.8x11.2x
Thu, 12 Oct 2023DKK 3.6tDKK 305.5bDKK 82.2b33.2x43.3x11.7x
Sat, 09 Sep 2023DKK 3.6tDKK 305.5bDKK 82.2b36.4x43.4x11.7x
Price to Earnings Ratio

43.4x


Total Market Cap: DKK 3.6tTotal Earnings: DKK 82.2bTotal Revenue: DKK 305.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 27.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.8x which is lower than its 3-year average PE of 27.7x.
  • The 3-year average PS ratio of 8.1x is higher than the industry's current PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 19% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-1.01%
Healthcare-1.85%
Healthtech2.85%
Life Sciences1.23%
Biotech0.19%
Medical Equipment-1.42%
Pharma-2.18%
Healthcare Services-4.17%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.7x.
    • Analysts are expecting annual earnings growth of 18.4%, which is higher than its past year's earnings growth of 9.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Pharma industry is expected to see its earnings growth to stay flat over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
COLO B ColoplastDKK 469.401.3%
+DKK 1.3b		-23.0%PE38.3x
DEMANT DemantDKK 289.401.7%
+DKK 1.0b		21.4%PE25.2x
HLUN B H. LundbeckDKK 43.161.1%
+DKK 475.8m		7.6%PE10.9x
ALK B ALK-AbellóDKK 210.801.0%
+DKK 443.8m		4.3%PE34.5x
BAVA Bavarian NordicDKK 222.001.7%
+DKK 287.6m		-5.8%PE10.9x

Latest News

AMBU B
DKK 70.95
Ambu
7D
-9.5%
1Y
-25.8%
Analysis Article • Aug 28

Ambu A/S Just Missed Earnings - But Analysts Have Updated Their Models

Last week, you might have seen that Ambu A/S ( CPH:AMBU B ) released its quarterly result to the market. The early...
NOVO B
DKK 293.90
Novo Nordisk
7D
-4.5%
1Y
-18.0%
BAVA
DKK 222.00
Bavarian Nordic
7D
1.7%
1Y
-5.8%
GUBRA
DKK 378.80
Gubra
7D
-5.9%
1Y
-2.8%
Analysis Article • Aug 26

Analyst Forecasts For Gubra A/S (CPH:GUBRA) Are Surging Higher

Celebrations may be in order for Gubra A/S ( CPH:GUBRA ) shareholders, with the analysts delivering a significant...
BIOPOR
DKK 1.16
BioPorto
7D
-6.9%
1Y
-14.6%
COLO B
DKK 469.40
Coloplast
7D
1.3%
1Y
-23.0%
New Narrative • Aug 25

Coloplast: A Rare Entry Point in Quality Healthcare

Republishing Note This article was originally published on my Substack on the 2nd of July 2026 and is republished here for wider distribution. Note: This report has been corrected since publication.
DEMANT
DKK 289.40
Demant
7D
1.7%
1Y
21.4%
HLUN B
DKK 43.16
H. Lundbeck
7D
1.1%
1Y
7.6%
Narrative Update • Aug 23

HLUN B: Advancing Neuroscience Pipeline Will Support Future Upside Potential

Analysts have raised their fair value estimate for H. Lundbeck from DKK 47.21 to DKK 48.73.
ALK B
DKK 210.80
ALK-Abelló
7D
1.0%
1Y
4.3%
GMAB
DKK 2,147.00
Genmab
7D
-2.2%
1Y
30.0%
Narrative Update • Aug 21

GMAB: Upcoming Oncology Readouts Will Support Commercial Transition And Offset Patent Cliff

Genmab's updated analyst price target has shifted modestly to DKK 2,930, as analysts factor in higher assumed revenue growth, a slightly lower profit margin profile, a higher discount rate and a lower future P/E multiple, supported by recent research citing confidence in Epkinly, rinatabart sesutecan and petosemtamab, stronger Q2 results, raised 2026 guidance and inclusion on a conviction list. Analyst Commentary Recent Street research on Genmab points to a cluster of supportive views, with several bullish analysts lifting price targets and upgrading ratings following Q2 results, updated 2026 guidance and progress across key oncology assets.
VIRO
DKK 10.10
ViroGates
7D
2.0%
1Y
3.1%
ZEAL
DKK 302.00
Zealand Pharma
7D
-7.6%
1Y
-32.0%
Analysis Article • Aug 18

Earnings Beat: Zealand Pharma A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of second-quarter numbers that could potentially...
CHEMM
DKK 475.00
ChemoMetec
7D
-4.4%
1Y
-7.6%
EMBLA
DKK 29.00
Embla Medical hf
7D
-3.8%
1Y
-8.2%
Analysis Article • Jul 24

Embla Medical hf. Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting Next

Embla Medical hf. ( CPH:EMBLA ) last week reported its latest second-quarter results, which makes it a good time for...
MONSO
DKK 0.32
Monsenso
7D
23.1%
1Y
39.1%